問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

林家齊

List

242Cases

2014-08-08 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-06-01 - 2014-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-07-01 - 2011-07-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-07-01 - 2023-10-27

Phase III

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

黃逸修
Taipei Veterans General Hospital

Division of Hematology & Oncology

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-04-15 - 2020-09-30

Phase I

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Condition/Disease

    Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Test Drug

    OBI-833 (Globo H-CRM197)/OBI-821

Participate Sites
4Sites

Recruiting4Sites

李凱靈
Taipei Medical University Hospital

Division of Hematology & Oncology

2019-03-01 - 2021-12-31

Phase I

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Condition/Disease

    Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Test Drug

    AbGn-107

Participate Sites
3Sites

Terminated3Sites

2015-09-24 - 2018-12-31

Phase III

Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.

  • Condition/Disease

    Urothelial Carcinoma

  • Test Drug

    JAVLOR

Participate Sites
4Sites

Terminated4Sites

2011-03-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2022-02-01 - 2022-04-06

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2023-03-01 - 2026-10-30

Phase I

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

  • Condition/Disease

    HER2 Mutant Non-small Cell Lung Cancer

  • Test Drug

    ELVN-002ENHERTUKADCYLA

Participate Sites
3Sites

Recruiting3Sites

1 21 22 23 24 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB